HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Malignant histiocytosis: therapeutic results in 27 children treated with a single polychemotherapy regimen.

Abstract
Twenty-seven children with histologically proven malignant histiocytosis were treated in the same institution from January, 1975 to December, 1986 with a combination chemotherapy regimen containing vincristine, cyclophosphamide, doxorubicine, and prednisone. Twenty-two patients achieved complete remission, one partial remission, and four no remission. Eight patients relapsed and were treated with Lomustine (CCNU), vinblastine, and bleomycin. In seven cases, a second complete remission was obtained. The overall survival rate is 81% at 5 years and the relapse-free survival rate is 54.5% at 5 years. Prognostic factors were fever and age under 10 at diagnosis, which were correlated with a higher incidence of relapse or no remission.
AuthorsL Brugieres, J M Caillaud, C Patte, C Rodary, A Bernard, C Kalifa, O Hartmann, J Lemerle
JournalMedical and pediatric oncology (Med Pediatr Oncol) Vol. 17 Issue 3 Pg. 193-6 ( 1989) ISSN: 0098-1532 [Print] United States
PMID2747592 (Publication Type: Journal Article)
Chemical References
  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
Topics
  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Child
  • Child, Preschool
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Lymphatic Diseases (drug therapy, pathology)
  • Male
  • Mechlorethamine (administration & dosage)
  • Prednisone (administration & dosage)
  • Procarbazine (administration & dosage)
  • Prognosis
  • Remission Induction
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: